Lapatinib May Boost Effectiveness of Drugs That Destroy Cancer Proteins by Blocking Resistance
PHILADELPHIA (August 30, 2022)—Researchers at Fox Chase Cancer Center have discovered that the drug efflux pump MDR1 promotes resistance to a promising new class of drugs called PROTACS—proteolysis-targeting chimeras.